In a big bowl, mix eggs, milk, salt and mustard together. Add bread, cheese and sausage. Mix together. Pour mixture into 9- ...

Cassava Sciences' stock rose 9% after completing an interim safety analysis for its Alzheimer's drug, Simufilam, but the company's future remains uncertain due to ongoing legal and scientific ...

For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is inert, and patients with Alzheimer’s ...

High-rolling investors have positioned themselves bearish on Cassava Sciences SAVA, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga ...

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today ...

The research behind Cassava Sciences’ Alzheimer’s drug candidate, simufilam, and the idea of targeting a brain protein called filamin, is based on a series of papers from a group at CUNY and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

WASHINGTON, Sept 26 (Reuters) - Shares of Cassava Sciences (SAVA.O), opens new tab fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for ...

Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic ...